1. Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients

3. Program Goals

4. The Incretin System: Response to Oral Glucose

5. Injected Incretin-based Agents: GLP-1 Receptor Agonists

6. Oral Incretin-based Agents: DPP-4 Inhibitors

7. Main Pathophysiological Defects in T2D

8. T2D Anti-Hyperglycemic Therapy: General Recommendations

10. Approaches to Intensifying Therapy in Patients Not At Goal on Basal Insulin

11. Adding Prandial Insulin to Basal Insulin: Key Challenges

12. Scientific Rationale for Combining Basal Insulin with a GLP-1 agonist

13. DPP- 4 Inhibitors as Add-ons to Basal Insulin

14. Pramlintide as Add-on to Basal Insulin

15. Twice-daily Exenatide as Add-on to Basal Insulin (Glargine)

16. Twice-daily Exenatide as Add-on to Basal Insulin (Glargine): Results

17. Metformin plus Liraglutide Followed by Add-on of Basal Insulin (Detemir)

18. Metformin plus Liraglutide Followed by Add-on of Basal Insulin (Detemir)

19. Oral Agents Plus Basal Insulin (Glargine) Followed by Add-on Lixisenatide*

20. Oral Agents Plus Basal Insulin (Glargine) Followed by Add-on Lixisenatide* (cont)

22. Other Safety Concerns With GLP-1 Receptor Agonists

23. Lixisenatide* vs Liraglutide: Effect on Postprandial Glucose Levels†

24. Comparison of Basal Insulin + Lixisenatide* and Basal-Plus Regimensa

25. IDegLira* vs Degludec* or Liraglutide Alone: Effect on HbA1c

26. IDegLira* vs Degludec* or Liraglutide Alone: Results

28. Abbreviations

29. Abbreviations (cont)

30. References

31. References (cont)

32. References (cont)

33. References (cont)

34. References (cont)

35. References (cont)

36. References (cont)

37. References (cont)

38. References (cont)

39. References (cont)

40. References (cont)

41. References (cont)